Brawn Biotech Limited (BOM:530207)
23.40
+0.70 (3.08%)
At close: Sep 7, 2026
Brawn Biotech Revenue
Brawn Biotech had revenue of 60.79M INR in the quarter ending June 30, 2026, with 4.85% growth. This brings the company's revenue in the last twelve months to 172.59M, up 13.56% year-over-year. In the fiscal year ending March 31, 2026, Brawn Biotech had annual revenue of 169.78M with 25.99% growth.
Revenue (ttm)
172.59M
Revenue Growth
+13.56%
P/S Ratio
0.41
Revenue / Employee
19.18M
Employees
9
Market Cap
70.21M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 169.78M | 35.02M | 25.99% |
| Mar 31, 2025 | 134.75M | -30.19M | -18.30% |
| Mar 31, 2024 | 164.95M | -57.42M | -25.82% |
| Mar 31, 2023 | 222.36M | 136.15M | 157.93% |
| Mar 31, 2022 | 86.21M | -263.55M | -75.35% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vivanza Biosciences | 1.17B |
| Beryl Drugs | 213.23M |
| Fabino Enterprises | 208.41M |
| Unjha Formulations | 152.79M |
| Decipher Labs | 138.51M |
| Norris Medicines | 76.00M |
| Ganga Pharmaceuticals | 28.28M |
| Emmessar Biotech & Nutrition | 23.78M |